OA
REGN icon

Oxbow Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

Oxbow Advisors’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.34M Buy
5,359
+25
+0.5% +$17K 0.27% 106
2026
Q1 		$4.12M Buy
5,334
+7
+0.1% +$5.36K 0.35% 77
2025
Q4 		$4.11M Buy
5,327
+80
+2% +$54.3K 0.36% 76
2025
Q3 		$2.95M Buy
+5,247
New +$2.97M 0.27% 90
2025
Q2 		– Sell
-3,653
Closed -$2.32M – 217
2025
Q1 		$2.32M Buy
+3,653
New +$2.51M 0.24% 81

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Oxbow Advisors's REGN Position: Q2 2026 in Review

Oxbow Advisors increased its Regeneron Pharmaceuticals (REGN) stake by 0.47% in Q2 2026, buying an estimated $17K and bringing the position to 5,359 shares worth $3.34M. The position accounts for 0.27% of the portfolio, ranked #106.

Oxbow Advisors first reported a position in REGN in Q1 2025 and has held it in 5 quarters since. The position peaked at $4.12M in Q1 2026. 1,335 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Oxbow Advisors held 5,359 shares of Regeneron Pharmaceuticals worth $3.34M as of Q2 2026.
  • Oxbow Advisors bought 25 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $17K.
  • Regeneron Pharmaceuticals made up 0.27% of Oxbow Advisors's portfolio in Q2 2026, its #106 holding.
  • Oxbow Advisors first reported a position in Regeneron Pharmaceuticals in Q1 2025 and has held it in 5 quarters since.
  • Oxbow Advisors's Regeneron Pharmaceuticals position peaked at $4.12M in Q1 2026.
  • 1,335 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Oxbow Advisors's 13F filing for Q2 2026, filed 7 Aug 2026.